Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease (MEIC)

Clinical Trial Phase IIa to Evaluate the Safety and Effectiveness of Treatment With Fat-derived Mesenchymal Allogenic Mesenchymal Troncal Cells in Patients With Single Inflammatory Stenosis in the Context of Crohn's Disease.

A phase II, national, multicenter, uncontrolled and open trial to evaluate the feasibility and safety of laparoscopic administration of adipose derived allogenic mesenchymals stem cells (adMSC), for the treatment of patients with a single inflammatory stenosis in the context of Crohn's disease.

Study Overview

• Status: Recruiting
• Conditions: Crohn Disease; Stenosis; Bowel
• Intervention / Treatment: Drug: Adipose derived allogenic mesenchymal stem cells (adAMSC)

Detailed Description

The hypothesis of the study is that the drug study administration will result in a anti-inflammatory effect, preventing the progression of the stenotic lesion and thus reducing the need to perform surgical resections.

A multicentre, national, uncontrolled and open-label pilot study will be performed. 20 adult patients fulfilling eligibility criteria will be included.

The trial is organized in screening period, treatment period and 6 follow-up visits.

The treatment visit will be done in operating theatre, as the study drug is administrated by laparoscopy with a total dose of 120 million cells prepared in a saline solution with a cell concentration of 10 million cells per millilitre.

Follow-up visits are divided into 4 visits that will take place every 6 weeks (+-7 days) until week 24; 1 additional follow-up visit will take place at week 36 and the last one at week 52.

Analytical controls (blood count, biochemistry and coagulation) will be carried out throughout the trial and biological samples will be taken in three visits (Screening, visit 3 and visit 6).

Abdominal MRI will be performed at baseline and in the end of study visit, to assess stenosis evolution.

The overall duration of the trial is 36 months from the start of recruitment to the last follow-up visit. The period planned for this trial is from september 2022 to september 2025.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Lucia Llanos; Phone Number: 3245 91 5504800; Email: lucia.llanos@quironsalud.es
• Study Contact Backup: Name: Eva Cerezo; Phone Number: 3214 91 5504800; Email: eva.cerezo@quironsalud.es

Study Locations

• Spain
  • Barcelona, Spain, 08035
    • Not yet recruiting
    • Hospital Universitario Valle de Hebrón
    • Contact: Marc Martí Gallostra; Email: mmgallostra@vhebron.net
  • Madrid, Spain, 28040
    • Recruiting
    • Hospital Universitario Fundacion Jimenez Diaz
    • Contact: Dolores Herreros Marcos; Email: dolores.herreros@quironsalud.es
  • Valencia, Spain, 46026
    • Not yet recruiting
    • Hospital Universitario y Politécnico La Fe
    • Contact: Mónica Millán Scheiding; Email: monicamillan72@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients who agree to participate and agree to give their written consent.
2. Patients older than 18 years and younger than 75 years
3. With Crohn's disease diagnosed at least 6 months before that meet clinical, endoscopic, histological and/or radiological criteria.
4. Presence of a single inflammatory stenotic lesion in the small intestine or ileocolic area with a maximum length of 5 cm, demonstrated by magnetic resonance enterography, which produces episodes of intestinal occlusion/subocclusion. Other inflammatory lesions are admittedly present, but only one should be identified as the obvious cause of the occlusion/subocclusion.

5. Patients treated with at least one biological drug and with inadequate response to maintenance doses and before intensification (either dose, interval or change/addition of another drug):

   1. antiTNF (for at least 14 week, include induction and/or maintenance doses): Infliximab, Adalimumab, Certolizumab.
   2. Anti-integrin (for at least 14 week, include induction and/or maintenance doses): Vedolizumab
   3. Anti-IL-12/23 (for at least 16 week, include induction and/or maintenance doses): Ustekinumab

6. Women of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraceptive measures for the duration of their participation in the study*

   • a woman is considered to be of childbearing potential (WOCBP), that is, fertile, after menarche and until she becomes postmenopausal, unless she is permanently infertile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

Highly effective methods are considered: combined hormonal contraception (containing estrogens and progestogens) associated with ovulation inhibition (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with ovulation inhibition (oral, injectable, implantable ), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, sexual abstinence

Exclusion Criteria:

1. Intra-abdominal abscesses larger than 3 cm not drained (surgically, by interventional radiology) or not treated with antibiotics. Patients may be included once the abscess has been drained (without the need to wait) or if they have received antibiotic treatment, once improvement has been confirmed with imaging tests.
2. Several intestinal obstruction that requires urgent surgery
3. Active outbreak of Crohn's disease requiring medical treatment, defined as abdominal pain, fever, bloody diarrhea and CRP greater than 10. The patient may be included once the condition has resolved, when the patient is on maintenance medication.
4. History of previous invasive neoplasia in the last 5 years. Patients with completely resected basal cell carcinoma of the skin may be included
5. History in the last 6 month of several, progressive or uncontrolled hepatic, hematological, gastrointestinal, renal, endocrine, pulmonary, cardiac, neurological or psychiatric disease
6. Patients with primary sclerosing cholangitis
7. Patients with known congenital or acquired immunodeficiency, including HIV
8. Known allergy or hypersensibility to penicillin or aminoglycosides; DMEN (dulbecco modified eagle´s medium), bovine serum, local anesthesic or gadolinium
9. Contraindication to perform MRI (pacemaker, hip replacement or severe claustrophobia).
10. Patients unwilling or unable to comply with study procedures.
11. Patients who are receiving or have received any investigational drug in the 3 months prior to the screening period
12. Major surgery or severe trauma in the previous 6 months.
13. Pregnant or lactating women.
14. Patients who have a contraindication for general anesthesia.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single Dose; This is an uncontrolled trial, phase IIa, proof of concept. Group control has not been included. All patients will receive one single dose of 120 million cells	Drug: Adipose derived allogenic mesenchymal stem cells (adAMSC); adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of complications	Number of complication associated with presurgery, surgery, IMP administration and postsurgery period	Through study completion, an average of 2 years
Change from baseline length and diameter of the stenosis	according to RMI	From screening visit to week 52
Crohn's disease activity index (CDAI) questionnaire score	Change from baseline in Crohn's disease activity index (CDAI) score (0-1100 points). Higher scores mean a worse outcome.	Through study completion, an average of 2 years
inflammatory bowel disease questionnaire (IBDQ32 )	Change from baseline in inflammatory bowel disease questionnaire (IBDQ32 ). 140-200 points, higher scores mean a better outcome.	Through study completion, an average of 2 years
patients with an obstructive episode who required resection surgery	number of patients with an obstructive episode who required resection surgery	Through study completion, an average of 2 years

Collaborators and Investigators

• Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
• Collaborators: Effice Servicios Para la Investigacion S.L.
• Investigators: Principal Investigator: Dolores Herreros, Hospital Fundación Jiménez Díaz

Study record dates

Study Major Dates

• Study Start (Actual): October 24, 2022
• Primary Completion (Estimated): June 1, 2025
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: August 22, 2022
• First Submitted That Met QC Criteria: August 26, 2022
• First Posted (Actual): August 30, 2022

Study Record Updates

• Last Update Posted (Actual): February 20, 2024
• Last Update Submitted That Met QC Criteria: February 19, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Pathological Conditions, Anatomical; Inflammatory Bowel Diseases; Crohn Disease; Constriction, Pathologic
• Other Study ID Numbers: FJD-MEIC-21-01; 2021-006068-26 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No